Close Menu

NEW YORK – Agilent Technologies reported after the close of the market on Tuesday that its first quarter revenues rose 14 percent year over year.

For the three months ended Jan. 31, Agilent said its revenues rose to $1.55 billion from $1.36 billion, beating analysts' average estimate of $1.44 billion. The firm said core revenues, which exclude the impact of currency and acquisitions and divestitures over the last 12 months, grew 11 percent in Q1.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.

CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.

According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.

In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.